Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | APP | P05067 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724733 | 0.86 | MAPT (0.47) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL11330644 | 0.85 | RAB9A (0.59) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL10271315 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL14218922 | 0.82 | RAB9A (0.56) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL19941789 | 0.82 | RAB9A (0.61) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL17038162 | 0.82 | RAB9A (0.56) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL15086785 | 0.82 | RAB9A (0.56) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL20653568 | 0.82 | RAB9A (0.56) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL20049378 | 0.81 | RAB9A (0.54) | RAB9AMAPTNPC1APPGAA | |
| SCHEMBL4390136 | 0.80 | NPC1 (0.53) | RAB9AMAPTNPC1APPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-04-27 | — | — | US | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115175909-A | Pyrrolopyridine and imidazopyridine antiviral compounds | 鲁汶天主教大学 | 2022-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130598-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | SARS1, TPI1, TPMT | RAB9A 2809/4885MAPT 33/4885NPC1 3063/4885 |
| US-12577242-B2 | Pyrrolopyridine and imidazopyridine antiviral compounds | SARS1, TPMT, ZC3HAV1 | RAB9A 1212/4885MAPT 443/4885NPC1 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.